SPRO Spero Therapeutics, Inc.
Price Chart
Executive Summary
Spero Therapeutics reported a significant turnaround in financial performance for Q4 and full-year 2025, driven by a 177% YoY revenue increase to $41.3M in the quarter, primarily from collaboration payments with GSK and Pfizer, while R&D expenses dropped 80% due to reduced trial activity. The company also announced that the FDA set a PDUFA date of June 18, 2026, for tebipenem HBr, an investigational oral antibiotic for cUTI, with cash reserves of $40.3M expected to fund operations into 2028.
Key Financial Metrics
Actionable Insight
Traders should monitor the June 18, 2026 FDA decision as a key catalyst; the strong cash position and reduced burn rate improve the company's runway and reduce near-term dilution risk, while the GSK partnership de-risks commercialization. The sharp improvement in profitability and revenue, driven by collaboration inflows, suggests improved financial sustainability pending regulatory outcome.
Key Facts
- Net income of $31.5M in Q4 2025 vs. net loss of $(20.9)M in Q4 2024
- Total revenue of $41.3M in Q4 2025, up from $15.0M in Q4 2024 (175% YoY growth)
- Full-year 2025 revenue of $66.8M vs. $48.0M in 2024
- R&D expenses fell to $5.6M in Q4 2025 from $28.8M in Q4 2024 due to completion of the PIVOT-PO trial
- FDA set PDUFA date of June 18, 2026, for tebipenem HBr NDA resubmission for cUTI
- Cash and equivalents: $40.3M as of Dec 31, 2025, expected to fund operations into 2028
- Received $25M milestone payment from GSK in Q1 2026 for NDA resubmission
Financial Impact
Revenue increased by $18.8M annually and $26.3M quarterly, while R&D costs decreased by $58.3M annually, leading to a $77.1M improvement in net income year-over-year
Risk Factors
- FDA approval of tebipenem HBr is not guaranteed and could be delayed or denied
- Future revenue depends heavily on milestone and collaboration payments, which are non-recurring
- Commercial success depends on GSK's execution, over which Spero has limited control
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263404 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 13, 2026
4w ago
|
8-K
| $2.76 $2.69 | ▼ −2.54% | ▼ −1.82% | $2.85 (+3.26%) |
|
Apr 27, 2026
6w ago
|
DEFA14A
| $2.67 $2.50 | ▼ −6.37% | ▼ −8.06% | $2.85 (+6.74%) |
|
Mar 26, 2026
11w ago
|
Press Release
| $2.33 $2.61 | ▲ +12.02% | ▲ +8.15% | $2.85 (+22.32%) |
|
Mar 18, 2026
12w ago
|
Press Release
| $2.47 $2.37 | ▼ −4.05% | ▼ −1.84% | $2.85 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access